{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:53:47Z","timestamp":1790420027720,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jns.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T17:27:20Z","timestamp":1517851640000},"page":"17-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Tardive dyskinesia: Epidemiology"],"prefix":"10.1016","volume":"389","author":[{"given":"Anelyssa","family":"D'Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jns.2018.02.007_bb0005","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.007_bb0010","first-page":"053736","article-title":"Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association","volume":"116","author":"Sarkar","year":"2017","journal-title":"BJPsych Bull"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mds.870130313","article-title":"Cinnarizine-induced parkinsonism: ten years later","volume":"13","author":"Mart\u00ed-Mass\u00f3","year":"1998","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.nrl.0000038585.58012.97","article-title":"Classification and treatment of tardive syndromes","volume":"9","author":"Fernandez","year":"2003","journal-title":"Neurologist"},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0010-440X(76)90007-9","article-title":"Diagnostic problems in Huntington's chorea and tardive dyskinesia","volume":"17","author":"Buxton","year":"1976","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00004714-199102000-00005","article-title":"The prevalence of tardive dyskinesia","volume":"11","author":"Woerner","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jns.2018.02.007_bb0045","first-page":"550","article-title":"Paroxysmal dyskinesia as the effect of megaphen","volume":"28","author":"Schonecker","year":"1957","journal-title":"Nervenarzt"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0050","first-page":"133","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.007_bb0070","series-title":"Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis","author":"Carbon","year":"2017"},{"key":"10.1016\/j.jns.2018.02.007_bb0075","first-page":"82","article-title":"Results from a prospective study of tardive dyskinesia development: preliminary findings over a 2-year period","volume":"18","author":"Kane","year":"1982","journal-title":"Psychopharmacol. Bull."},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2018.02.007_bb0085","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2018.02.007_bb0090","first-page":"508","article-title":"Prevalence of tardive dyskinesia","volume":"40","author":"Tepper","year":"1979","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0021-9681(87)90047-6","article-title":"Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population","volume":"40","author":"Morgenstern","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"9","key":"10.1016\/j.jns.2018.02.007_bb0100","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane","year":"1993","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1532-5415.1999.tb01595.x","article-title":"Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients","volume":"47","author":"Jeste","year":"1999","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.jns.2018.02.007_bb0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.007_bb0115","article-title":"Quetiapine versus typical antipsychotic medications for schizophrenia","volume":"5","author":"Suttajit","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00427742","article-title":"Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine","volume":"59","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/ajp.138.2.189","article-title":"Clonazepam and phenobarbital in tardive dyskinesia","volume":"138","author":"Bobruff","year":"1981","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/106002808401800408","article-title":"Alprazolam reversal of reserpine-induced depression in patients with compensated tardive dyskinesia","volume":"18","author":"Holt","year":"1984","journal-title":"Drug Intelligence & Clin. Pharmacy"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-198508000-00017","article-title":"Tardive dystonia: treatment with trihexyphenidyl","volume":"5","author":"Wolf","year":"1985","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jns.2018.02.007_bb0140","first-page":"673","article-title":"Tardive dyskinesia successfully treated with alprazolam","volume":"82","author":"Jordan","year":"1990","journal-title":"J. Natl. Med. Assoc."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0145","first-page":"67","article-title":"A case of tardive Tourette-like syndrome","volume":"46","author":"Kuniyoshi","year":"1992","journal-title":"Jap. J. Psychiatry Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.02.007_bb0150","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1176\/appi.ajp.159.11.1948","article-title":"Tardive dyskinesia with risperidone and anticholinergics","volume":"159","author":"Suzuki","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11920-011-0202-6","article-title":"Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment","volume":"13","author":"Lerner","year":"2011","journal-title":"Curr. Psychiatry Rep."},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00004714-199404000-00012","article-title":"Tardive dyskinesia-like syndrome associated with lithium and carbamazepine","volume":"14","author":"Lazarus","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0165","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00004714-199606000-00016","article-title":"Paroxetine and tardive dyskinesia","volume":"16","author":"Botsaris","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jns.2018.02.007_bb0170","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1176\/ps.47.9.991","article-title":"Tardive dyskinesia associated with fluoxetine","volume":"47","author":"Dubovsky","year":"1996","journal-title":"Psychiatric Services (Washington, DC)"},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0175","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.genhosppsych.2008.10.001","article-title":"Akathisia and abnormal movements of the upper extremities with venlafaxine and methimazole","volume":"31","author":"Ng","year":"2009","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0180","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pnpbp.2008.12.001","article-title":"Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder","volume":"33","author":"Park","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0185","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1176\/appi.neuropsych.11060144","article-title":"Venlafaxine causing akathisia: a case report","volume":"24","author":"George","year":"2012","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/JCP.0b013e31828bf059","article-title":"The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression","volume":"33","author":"Blumberger","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/pcn.12017","article-title":"Venlafaxine-related akathisia side-effects and management in a depressed patient","volume":"67","author":"Lai","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0200","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4103\/0253-7613.144948","article-title":"Venlafaxine induced akathisia: a case report","volume":"46","author":"Grover","year":"2014","journal-title":"Ind. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/2237-6089-2015-0084","article-title":"Venlafaxine induced akathisia: a case report","volume":"38","author":"Ceylan","year":"2016","journal-title":"Trends in Psychiatry and Psychotherapy"},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1528-1157.1977.tb04984.x","article-title":"Phenytoin-induced hyperkinesia","volume":"18","author":"Luhdorf","year":"1977","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0215","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/cpt1979256767","article-title":"Drug-related transient dyskinesias","volume":"25","author":"Osifo","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.jns.2018.02.007_bb0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00004714-199004000-00026","article-title":"Acute dystonic reaction induced by a monoamine oxidase inhibitor","volume":"10","author":"Jarecke","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jns.2018.02.007_bb0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors","volume":"57","author":"Leo","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jns.2018.02.007_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1353-8020(99)00015-2","article-title":"Drug-induced tardive syndromes","volume":"5","author":"Orti-Pareja","year":"1999","journal-title":"Parkinsonism Relat. Disord."},{"issue":"S1","key":"10.1016\/j.jns.2018.02.007_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1092852916000730","article-title":"Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia","volume":"21","author":"Meyer","year":"2016","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0240","first-page":"34","article-title":"A tardive dyskinesia-like syndrome after amitriptyline treatment","volume":"1","author":"Woogen","year":"1981","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0245","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0269881103174003","article-title":"Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia","volume":"17","author":"Hansen","year":"2003","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clineuro.2004.01.008","article-title":"Citalopram-induced jaw tremor","volume":"107","author":"Tarlaci","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0255","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.pnpbp.2008.05.002","article-title":"Tardive dystonia and tardive sensory syndrome related to trazodone: a case report","volume":"32","author":"Lin","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2018.02.007_bb0260","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.pmrj.2010.05.007","article-title":"A rare case of tardive dyskinesia and akathisia induced by citalopram","volume":"2","author":"Birthi","year":"2010","journal-title":"PM & R"},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.genhosppsych.2010.04.009","article-title":"Duloxetine-related tardive dystonia and tardive dyskinesia: a case report","volume":"32","author":"Chen","year":"2010","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0270","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JCP.0b013e3182686619","article-title":"Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report","volume":"32","author":"Albayrak","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1601-5215.2011.00643.x","article-title":"Fluoxetine-induced tardive dyskinesia in a patient with Parkinson's disease","volume":"24","author":"Raidoo","year":"2012","journal-title":"Acta Neuropsychiatrica."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ncl.2014.09.011","article-title":"Drug-induced movement disorders","volume":"33","author":"Mehta","year":"2015","journal-title":"Neurol. Clin."},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0285","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004714-199710000-00007","article-title":"Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses","volume":"17","author":"Gill","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0290","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3949\/ccjm.57.4.367","article-title":"Carbamazepine-induced dyskinesia and ophthalmoplegia","volume":"57","author":"Schwartzman","year":"1990","journal-title":"Cleve. Clin. J. Med."},{"issue":"10","key":"10.1016\/j.jns.2018.02.007_bb0295","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJM197509042931008","article-title":"Oral facial dyskinesia accociated with prolonged use of antihistaminic decongestants","volume":"293","author":"Thach","year":"1975","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2018.02.007_bb0300","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.410110423","article-title":"Hydroxyzine-associated tardive dyskinesia","volume":"11","author":"Clark","year":"1982","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0305","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.parkreldis.2014.02.005","article-title":"Drug induced oromandibular dystonia: a case related to prolonged use of cetirizine","volume":"20","author":"Pellecchia","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.02.007_bb0310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1440-1819.2007.01732.x","article-title":"Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam","volume":"61","author":"Yamamoto","year":"2007","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.jns.2018.02.007_bb0315","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.1993.00410120051007","article-title":"The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders","volume":"153","author":"Ganzini","year":"1993","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0320","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270007312258","article-title":"Metoclopramide, an increasingly recognized cause of tardive dyskinesia","volume":"48","author":"Kenney","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jns.2018.02.007_bb0325","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40264-016-0418-9","article-title":"The safety of metoclopramide in children: a systematic review and meta-analysis","volume":"39","author":"Lau Moon Lin","year":"2016","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2009.04189.x","article-title":"Review article: metoclopramide and tardive dyskinesia","volume":"31","author":"Rao","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.jns.2018.02.007_bb0335","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1176\/ajp.145.5.613","article-title":"Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium","volume":"145","author":"Waddington","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.007_bb0340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.155.1.55","article-title":"Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy","volume":"155","author":"Dinan","year":"1989","journal-title":"British J. of Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0345","first-page":"22","article-title":"A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients","volume":"57","author":"Ghadirian","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2018.02.007_bb0350","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4140\/TCP.n.2006.229","article-title":"Polypharmacy in a 75-year-old patient with schizoaffective disorder","volume":"21","author":"Breden","year":"2006","journal-title":"Consult. Pharm."},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0355","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pnpbp.2009.09.022","article-title":"Resolution of tardive dystonia in a patient with bipolar disorder treated with clozapine: a case report","volume":"34","author":"Kwan","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2018.02.007_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/157488612800492807","article-title":"Atypical presentation of tardive dyskinesia associated with risperidone long-acting injection as maintenance treatment in bipolar affective disorder: a case report","volume":"7","author":"Chung","year":"2012","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jns.2018.02.007_bb0365","article-title":"Clozapine-induced microseizures, orofacial dyskinesia, and speech dysfluency in an adolescent with treatment resistant early onset schizophrenia on concurrent lithium therapy","volume":"2017","author":"Rachamallu","year":"2017","journal-title":"Case Rep. Psychiatry."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T12:43:44Z","timestamp":1533905024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":73,"alternative-id":["S0022510X18300650"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.007","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tardive dyskinesia: Epidemiology","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}